Dr. Reddy's Laboratories (NYSE:RDY) Sets New 1-Year Low - What's Next?

Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Get Free Report) hit a new 52-week low during trading on Friday . The company traded as low as $12.50 and last traded at $12.82, with a volume of 7014 shares trading hands. The stock had previously closed at $13.24.

Analyst Ratings Changes

Separately, Nomura cut shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a report on Thursday, December 19th.

Dr. Reddy's Laboratories Price Performance

The stock has a market cap of $10.64 billion, a P/E ratio of 20.29 and a beta of 0.51. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. The business has a 50 day simple moving average of $13.26 and a 200-day simple moving average of $14.43.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, sell-side analysts forecast that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.

Institutional Trading of Dr. Reddy's Laboratories

A number of institutional investors have recently modified their holdings of RDY. EverSource Wealth Advisors LLC lifted its holdings in Dr. Reddy's Laboratories by 423.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company's stock worth $29,000 after purchasing an additional 1,507 shares in the last quarter. Glass Jacobson Investment Advisors llc boosted its stake in Dr. Reddy's Laboratories by 400.0% during the fourth quarter. Glass Jacobson Investment Advisors llc now owns 2,000 shares of the company's stock valued at $32,000 after buying an additional 1,600 shares during the period. POM Investment Strategies LLC grew its position in Dr. Reddy's Laboratories by 400.0% during the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock worth $36,000 after buying an additional 1,820 shares in the last quarter. Farther Finance Advisors LLC increased its stake in Dr. Reddy's Laboratories by 461.0% in the 4th quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company's stock worth $40,000 after acquiring an additional 2,093 shares during the last quarter. Finally, Allworth Financial LP raised its holdings in shares of Dr. Reddy's Laboratories by 447.8% in the 4th quarter. Allworth Financial LP now owns 2,728 shares of the company's stock valued at $41,000 after acquiring an additional 2,230 shares in the last quarter. 3.85% of the stock is currently owned by hedge funds and other institutional investors.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.